
Publication Strategy Navigator
Plan and validate pharmaceutical publication strategies with regulatory alignment
What You Can Do
You can develop comprehensive publication roadmaps that align with regulatory requirements, product lifecycle phases, and commercial objectives. This skill synthesizes literature landscapes, identifies knowledge gaps, targets optimal journals, coordinates multi-author manuscripts, and de-risks timelines through data readiness pre-screening—transforming scattered publication ideas into validated, actionable strategies.
Features
Align 2-3 year manuscript roadmaps to indication development phases, regulatory milestones, and launch timelines
Analyze 50+ articles to identify knowledge gaps, positioning opportunities, and claims validation
Pre-screen manuscripts against regulatory requirements before resource commitment
Define roles, responsibilities, and timelines with institutional coordination
Evaluate impact factor, peer review speed, audience alignment, and competitive positioning
Coordinate overlapping manuscripts across clinical trials, regulatory submissions, and launches
De-risk timelines by identifying data gaps and analysis prerequisites
Example Output
Example 1: Product Launch Strategy
Input: New cardiovascular indication launching Q3 2025
Output:
- Year 1 (Pre-Launch): 2 mechanism-of-action manuscripts in high-impact journals
- Year 2 (Launch + 6mo): 3 real-world evidence studies in cardiology titles
- Year 3 (Mature): 1 health economics analysis + 2 case series in specialized publications
- Regulatory alignment: All submissions reviewed against FDA guidance on comparative claims
Example 2: Journal Selection Matrix
Input: Phase 3 efficacy manuscript for dermatology
Output:
| Journal | Impact | Review Speed | Audience Fit | Competitive Risk | Recommendation |
|---|---|---|---|---|---|
| JAMA Derm | 7.2 | 12-16 weeks | Broad | Medium | Primary target |
| Dermatology Therapy | 3.1 | 6-8 weeks | Specialists | Low | Fast-track option |
Example 3: Author Coordination Timeline
Input: Multi-institutional Phase 2b manuscript with 8 co-authors
Output:
- Week 1-2: Outline + data lock approval (Lead author + 2 key advisors)
- Week 3-6: Draft sections assigned (Authors 3-8, specific responsibilities listed)
- Week 7: Integrated draft review (Lead author)
- Week 8-9: Revision cycles (Institution review checkpoints)
- Week 10: Submission-ready manuscript
What's Included
- SKILL.md instruction file with Publication Strategy Navigator prompts:
- Publication Strategy Template: 2-3 year roadmap framework linked to product lifecycle and regulatory milestones
- Literature Synthesis Worksheet: Gap analysis and positioning opportunity matrix
- Journal Targeting Checklist: Impact, audience, review speed, and competitive positioning criteria
- Author/Contributor Matrix Template: Roles, responsibilities, timelines, and institutional tracking
- Publication Calendar Framework: Manuscript coordination across clinical trials and commercial milestones
Who It's For
- Medical Affairs Managers — developing publication strategies aligned with regulatory and commercial objectives
- Clinical Trial Leaders — coordinating manuscript timelines with trial phases and data availability
- Regulatory Affairs Specialists — validating publication compliance with FDA/EMA guidance and comparative claims policy
- Scientific Communications Teams — planning literature positioning and knowledge gap closure
- Commercial Leadership — evaluating publication ROI and market access impact of scientific strategy
Best For
- 2-3 year publication roadmap development for new product launches or indications
- Literature synthesis projects analyzing 50+ articles for gaps and claims support
- Multi-manuscript coordination across overlapping timelines and shared datasets
- Journal selection and targeting for high-stakes efficacy or health economics manuscripts
- Author/institutional coordination across 5+ co-authors or multi-site trials
- Regulatory compliance pre-screening before manuscript submission
- Publication strategy presentations for leadership, advisory boards, or regulatory discussions
